Locally advanced or metastatic prostate Prostate cancer is a major

as reported by Borgen Nonetheless, this study provides important insight into the effects of ZOL on DTCs within the bone marrow. In conclusion, the results from the current trial are consistent with the antitumor properties of ZOL demonstrated in numerous preclinical studies. Elimination of DTCs by ZOL, as reported in our study, may have profound implications for long-term disease outcomes Tacrolimus and survival by reducing the risk of early or late recurrence in patients with BC. Extended follow-up will provide further insight into the clinical benefit of ZOL treatment in this setting. However, additional studies are needed to investigate the role of DTCs in disease progression. AstraZeneca, and research grants from Roche. Dr WJ has received lecture honoraria and research grants from Novartis.
Dr H-JL has received lecture honoraria from Roche, Novartis, Sanofi, GlaxoSmithKline, and Pfizer, and is an advisory Rhein inhibitor board member for Roche, Novartis, Pfizer, Fresenius, and BMS. Dr JH has received lecture honoraria from Novartis, and is an advisory board member for Roche, Novartis, and Amgen. Dr TF has received honoraria from Roche, Novartis, and AstraZeneca, and research grants from Roche. Dr BW is employed by Novartis. Dr DW has received research grants from Novartis and Roche. Drs GG, PH, SB, and BK have declared no conflict of interest. Background Long-term hormone therapy alone Taurine 107-35-7 is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE—an international, open-label, randomised controlled trial—uses a novel multiarm, multistage design to assess whether the early additional use of one or two drugs improves survival in men starting first-line, long-term hormone therapy.
Here, we report the preplanned, second intermediate analysis comparing hormone therapy plus celecoxib with hormone therapy alone. Methods Eligible patients were men with newly diagnosed or rapidly relapsing buy Indole-3-carbinol prostate cancer who were starting long-term hormone therapy for the first time. Hormone therapy was given as standard care in all trial arms, with local radiotherapy encouraged for newly diagnosed patients without distant metastasis. Randomisation was done using minimisation with a random element across seven stratification factors. Patients randomly allocated to arm D received celecoxib 400 mg twice daily, given orally, until 1 year or disease progression.
The intermediate outcome was failure-free survival in three activity stages; the primary outcome was overall survival in a subsequent social roles efficacy stage. Research arms were compared pairwise against the control arm on an intention-to-treat basis. Accrual of further patients was discontinued in any research arm showing safety concerns or insufficient evidence of activity compared with the control arm. The minimum targeted activity at the second intermediate activity stage was a hazard ratio of. This trial is registered with ClinicalTrials.gov, , and with Current Controlled Trials. Interpretation Celecoxib 400 mg twice daily for up to 1 year is insufficiently active in patients starting hormone therapy for high-risk prostate cancer, and we do not recommend its use in this setting. Accrual continues seamlessly to the other research arms and follow-up of all arms will continue to assess effects on overall survival. Funding Cancer Research UK, Pfizer, Novartis, Sanofi-Aventis, Medical Research Council. Introduction treatment for locally advanced or metastatic prostate Prostate cancer is a major.